Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Elly Lugtenburg; JM Zijlstra; Jeanette Doorduijn; LH Bohmer; M Hoogendoorn; HW Berenschot; A Beeker; NC van der Burg-de Graauw; HC Schouten; YM Bilgin; MJ Kersten; HR Koene; AHE Herbers; D Jong; N Hijmering; King Lam; D Chitu; RE Brouwer; GW van Imhoff

doi:10.1111/bjh.16087

Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Elly Lugtenburg, JM Zijlstra, Jeanette Doorduijn, LH Bohmer, M Hoogendoorn, HW Berenschot, A Beeker, NC van der Burg-de Graauw, HC Schouten, YM Bilgin, MJ Kersten, HR Koene, AHE Herbers, D Jong, N Hijmering, King Lam, D Chitu, RE Brouwer, GW van Imhoff

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Original language	Undefined/Unknown
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/bjh.16087
Publication status	Published - 2019

Access to Document

10.1111/bjh.16087

http://hdl.handle.net/1765/118058

Cite this

Lugtenburg, E., Zijlstra, JM., Doorduijn, J., Bohmer, LH., Hoogendoorn, M., Berenschot, HW., Beeker, A., van der Burg-de Graauw, NC., Schouten, HC., Bilgin, YM., Kersten, MJ., Koene, HR., Herbers, AHE., Jong, D., Hijmering, N., Lam, K., Chitu, D., Brouwer, RE., & van Imhoff, GW. (2019). Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. British Journal of Haematology. https://doi.org/10.1111/bjh.16087

@article{3781fc65be4c4731abbb093a5566e845,

title = "Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study",

author = "Elly Lugtenburg and JM Zijlstra and Jeanette Doorduijn and LH Bohmer and M Hoogendoorn and HW Berenschot and A Beeker and {van der Burg-de Graauw}, NC and HC Schouten and YM Bilgin and MJ Kersten and HR Koene and AHE Herbers and D Jong and N Hijmering and King Lam and D Chitu and RE Brouwer and {van Imhoff}, GW",

year = "2019",

doi = "10.1111/bjh.16087",

language = "Undefined/Unknown",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

}

Lugtenburg, E, Zijlstra, JM, Doorduijn, J, Bohmer, LH, Hoogendoorn, M, Berenschot, HW, Beeker, A, van der Burg-de Graauw, NC, Schouten, HC, Bilgin, YM, Kersten, MJ, Koene, HR, Herbers, AHE, Jong, D, Hijmering, N, Lam, K, Chitu, D, Brouwer, RE & van Imhoff, GW 2019, 'Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study', British Journal of Haematology. https://doi.org/10.1111/bjh.16087

Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. / Lugtenburg, Elly; Zijlstra, JM; Doorduijn, Jeanette et al.

In: British Journal of Haematology, 2019.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

AU - Lugtenburg, Elly

AU - Zijlstra, JM

AU - Doorduijn, Jeanette

AU - Bohmer, LH

AU - Hoogendoorn, M

AU - Berenschot, HW

AU - Beeker, A

AU - van der Burg-de Graauw, NC

AU - Schouten, HC

AU - Bilgin, YM

AU - Kersten, MJ

AU - Koene, HR

AU - Herbers, AHE

AU - Jong, D

AU - Hijmering, N

AU - Lam, King

AU - Chitu, D

AU - Brouwer, RE

AU - van Imhoff, GW

PY - 2019

Y1 - 2019

U2 - 10.1111/bjh.16087

DO - 10.1111/bjh.16087

M3 - Article

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -